



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

June 23, 2022

Eric A. Adams
President and Chief Executive Officer
InMed Pharmaceuticals Inc.
815 W. Hastings Street, Suite 310
Vancouver, B.C. V6C 1B4
Canada

Re: InMed Pharmaceuticals Inc.
Registration Statement on Form S-1
Filed June 21, 2022
File No. 333-265731

Dear Mr. Adams:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Chris Edwards at 202-551-6761 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Brian Fenske, Esq.